<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>330-MEDICATIONS-AT-THE-ORIGIN-OF-ORTHOSTATIC-HYPOTENSION.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MEDICATIONS AT THE ORIGIN OF ORTHOSTATIC HYPOTENSION" code="N05AA-001" /></DRUG1>
<DRUG2>
<DRUG name="DAPOXETINE" rxcui="69394">
<ATC code="G04BX14" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects, especially of the vertigo and fainting type</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-with the type 5 phospohdisterase inhibitors</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>330-MEDICATIONS-AT-THE-ORIGIN-OF-ORTHOSTATIC-HYPOTENSION.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MEDICATIONS AT HE ORIGIN OF ORTHOSTATIC HYPOTENSION" code="N05AA-001" /></DRUG1>
<DRUG2>
<CLASS name="MEDICATIONS THAT LOWER BLOOD PRESSURE " code="MLBP" /></DRUG2>
<DESCRIPTION>Risk of increase of hypotension, especially orthostatic</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
</INTERACTIONS>
